Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1921 +/- Carboplatin in Recurrent Ovarian Cancer
NCT06211023Phase 3Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2024
- Primary completion
- Jun 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
01
Overview
A Phase 3 trial of tizetatug rezetecan in epithelial ovarian cancer (EOC), sponsored by Suzhou Suncadia Biopharmaceutical. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
tizetatug rezetecan
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT06211023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211023.